Cellular therapy in Parkinson disease may work differently.
Unlike the acute and evolving changes of acute stroke,
Parkinson disease is characterized by chronic degenerative changes
in the CNS.
SB623 is a cell therapy derived from bone marrow mesenchymal
stem cells (MSCs) that has immunosuppressive and angiogenic effects.
A study using intracranial injection of SB623 gene modified MSCs in Parkinson disease was discussed.
Patients met the primary endpoint and improved from their baseline.
ｂｌｄ（超頭強いＩＱ170↑）
英文では、明確に、ＡＡＮです。
Cell therapy for Parkinson disease
Cellular therapy in Parkinson disease may work differently.
Unlike the acute and evolving changes of acute stroke,
Parkinson disease is characterized by chronic degenerative changes
in the CNS.
SB623 is a cell therapy derived from bone marrow mesenchymal
stem cells (MSCs) that has immunosuppressive and angiogenic effects.
A study using intracranial injection of SB623 gene modified MSCs in Parkinson disease was discussed.
Patients met the primary endpoint and improved from their baseline.
パーキンソン病の細胞療法
パーキンソン病における細胞療法は、異なった働きをするかもしれません。
急性脳卒中の急性および進行性の変化とは異なり、パーキンソン病は
中枢神経系の慢性変性変化を特徴としています。
SB623は骨髄間葉系幹細胞（MSC）由来の免疫抑制および血管新生作用を
持つ細胞療法です。
パーキンソン病におけるSB623遺伝子修飾MSCの頭蓋内注射を用いた研究が
議論された。 患者は主要評価項目を達成し、ベースラインから改善しました。